Related Experiment Video
Updated: Dec 8, 2025
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma
1Department of Dermatology, University Hospital of Magdeburg, Magdeburg, Germany.
Abstract:
Uveal melanoma is the most common form of eye cancer and has a poor prognosis. Although the primary tumor in most cases is treated effectively by local surgery or radiotherapy, over 50 % of patients develop systemic metastasis, especially in the liver. In contrast to cutaneous melanoma, there is no standard-of-care treatment for metastasized uveal melanoma. Recently, oncogenic driver mutations in GNAQ or GNA11 were identified in about 85 % of uveal melanomas, which lead to constitutively active signaling in the Gαq/11 pathway and its downstream effectors. Direct targeting of deregulated Gαq/11 signaling might therefore be a therapeutic option for patients with uveal melanoma. In our study we identified the cyclic depsipeptide FR-900359, which is isolated from the evergreen plant Ardisia crenata as an effective inhibitor of constitutively active Gαq/11 proteins and their downstream targets. Although our data are preliminary, they might contribute to a future treatment option for patients with metastasized uveal melanoma.
Insights
A novel plant-derived compound, FR-900359, effectively inhibits Gαq/11 signaling, offering a potential new treatment for metastatic uveal melanoma, a rare eye cancer with limited therapeutic options.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Uveal melanoma is the most common primary intraocular malignancy with a high propensity for metastasis.
- Current treatments for metastatic uveal melanoma are limited, highlighting an unmet clinical need.
- Activating mutations in GNAQ or GNA11 drive signaling in approximately 85% of uveal melanomas.
Purpose of the Study:
- To identify potential therapeutic targets for uveal melanoma.
- To investigate the efficacy of inhibiting the Gαq/11 pathway in uveal melanoma.
Main Methods:
- Identification of the cyclic depsipeptide FR-900359 from Ardisia crenata.
- Assessment of FR-900359's inhibitory effects on constitutively active Gαq/11 proteins and downstream signaling pathways.
Main Results:
- FR-900359 demonstrated potent inhibition of Gαq/11 signaling.
- The compound effectively targeted downstream effectors of the Gαq/11 pathway.
Conclusions:
- FR-900359 represents a promising therapeutic candidate for uveal melanoma.
- Targeting the Gαq/11 pathway with FR-900359 may offer a novel treatment strategy for patients with metastatic disease.
More Related Videos
05:46Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...